PP Defence Therapeutics | Innovation News Network Science, Research & Innovation News Mon, 06 Jan 2025 10:09:27 +0000 en-GB hourly 1 https://wordpress.org/?v=6.5.5 Defence Therapeutics expands patent portfolio, bolstering innovation in cancer and vaccine therapies /defence-therapeutics-expands-patent-portfolio/54213/?utm_source=rss&utm_medium=rss&utm_campaign=defence-therapeutics-expands-patent-portfolio /defence-therapeutics-expands-patent-portfolio/54213/#respond Mon, 06 Jan 2025 10:09:27 +0000 /?p=54213 Defence Therapeutics Inc. has announced the significant expansion of its patent portfolio with several crucial issuances and allowances.

The post Defence Therapeutics expands patent portfolio, bolstering innovation in cancer and vaccine therapies appeared first on Innovation News Network.

]]> /defence-therapeutics-expands-patent-portfolio/54213/feed/ 0 Dr Elias Theodorou joins Defence board of directors /dr-elias-theodorou-joins-defence-board-of-directors/54126/?utm_source=rss&utm_medium=rss&utm_campaign=dr-elias-theodorou-joins-defence-board-of-directors /dr-elias-theodorou-joins-defence-board-of-directors/54126/#respond Fri, 20 Dec 2024 11:36:20 +0000 /?p=54126 Dr Elias Theodorou is a molecular biologist with over 25 years of experience in the healthcare sector. Read more here.

The post Dr Elias Theodorou joins Defence board of directors appeared first on Innovation News Network.

]]> /dr-elias-theodorou-joins-defence-board-of-directors/54126/feed/ 0 Defence announces Dr Maxime Parisotto as CSO, Director of Science and Business Development /defence-announces-dr-maxime-parisotto-as-cso-director-of-science-and-business-development/53309/?utm_source=rss&utm_medium=rss&utm_campaign=defence-announces-dr-maxime-parisotto-as-cso-director-of-science-and-business-development /defence-announces-dr-maxime-parisotto-as-cso-director-of-science-and-business-development/53309/#respond Mon, 25 Nov 2024 11:33:09 +0000 /?p=53309 Dr Maxime Parisotto is a seasoned biochemist with over 20 years of experience spanning academic research, drug development, and innovation.

The post Defence announces Dr Maxime Parisotto as CSO, Director of Science and Business Development appeared first on Innovation News Network.

]]> /defence-announces-dr-maxime-parisotto-as-cso-director-of-science-and-business-development/53309/feed/ 0 Defence Therapeutics welcomes Dr Svetlana Selivanova to board of directors /defence-therapeutics-welcomes-dr-svetlana-selivanova-to-board-of-directors/52768/?utm_source=rss&utm_medium=rss&utm_campaign=defence-therapeutics-welcomes-dr-svetlana-selivanova-to-board-of-directors /defence-therapeutics-welcomes-dr-svetlana-selivanova-to-board-of-directors/52768/#respond Wed, 13 Nov 2024 10:10:20 +0000 /?p=52768 Defence Therapeutics has announced that Dr Svetlana Selivanova has joined its board of directors, effective immediately.

The post Defence Therapeutics welcomes Dr Svetlana Selivanova to board of directors appeared first on Innovation News Network.

]]> /defence-therapeutics-welcomes-dr-svetlana-selivanova-to-board-of-directors/52768/feed/ 0 Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval /defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval/51916/?utm_source=rss&utm_medium=rss&utm_campaign=defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval /defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval/51916/#respond Wed, 24 Jul 2024 18:29:35 +0000 /?p=51916 Defence Therapeutics Inc. has announced a significant milestone in its radio-immuno-conjugates project. The Canadian Nuclear Research Initiative Health (CNRI-H) Program application by Defence Therapeutics has been approved by the Canadian Nuclear Laboratories (CNL), facilitating the acceleration of their innovative research. Focus of the CNRI-H project The CNRI-H project by Defence Therapeutics will concentrate on the synthesis and evaluation […]

The post Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval appeared first on Innovation News Network.

]]> /defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval/51916/feed/ 0 Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX) /defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox/51915/?utm_source=rss&utm_medium=rss&utm_campaign=defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox /defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox/51915/#respond Mon, 08 Jul 2024 18:29:34 +0000 /?p=51915 Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma. Defence Therapeutics Inc, a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter (“NOL”) from Health Canada […]

The post Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX) appeared first on Innovation News Network.

]]> /defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox/51915/feed/ 0 Defence Therapeutics’ ARM-X vaccine completely inhibits ovarian cancer growth in treated animals /defence-therapeutics-arm-x-vaccine-inhibits-ovarian-cancer-growth-treated-animals/51914/?utm_source=rss&utm_medium=rss&utm_campaign=defence-therapeutics-arm-x-vaccine-inhibits-ovarian-cancer-growth-treated-animals /defence-therapeutics-arm-x-vaccine-inhibits-ovarian-cancer-growth-treated-animals/51914/#respond Tue, 25 Jun 2024 18:29:33 +0000 /?p=51914 Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor. Using Defence’s Accum® platform, Defence previously demonstrated that AccuTOX® treatment of MSCs results in the […]

The post Defence Therapeutics’ ARM-X vaccine completely inhibits ovarian cancer growth in treated animals appeared first on Innovation News Network.

]]> /defence-therapeutics-arm-x-vaccine-inhibits-ovarian-cancer-growth-treated-animals/51914/feed/ 0